Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
APLT 
Applied Therapeutics Inc (APLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: APLT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.17
1 Year Target Price $3.17
| 2 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.72% | Avg. Invested days 28 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 60.57M USD | Price to earnings Ratio - | 1Y Target Price 3.17 |
Price to earnings Ratio - | 1Y Target Price 3.17 | ||
Volume (30-day avg) 4 | Beta 2.06 | 52 Weeks Range 0.29 - 10.62 | Updated Date 09/15/2025 |
52 Weeks Range 0.29 - 10.62 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -92057.03% |
Management Effectiveness
Return on Assets (TTM) -84.32% | Return on Equity (TTM) -150.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 32752499 | Price to Sales(TTM) 500.59 |
Enterprise Value 32752499 | Price to Sales(TTM) 500.59 | ||
Enterprise Value to Revenue 270.68 | Enterprise Value to EBITDA -9.71 | Shares Outstanding 144012000 | Shares Floating 120214121 |
Shares Outstanding 144012000 | Shares Floating 120214121 | ||
Percent Insiders 5.61 | Percent Institutions 65.43 |
Upturn AI SWOT
Applied Therapeutics Inc
Company Overview
History and Background
Applied Therapeutics, Inc. was founded in 2016. It is a biopharmaceutical company focused on developing novel therapeutics for unmet medical needs in rare and debilitating diseases.
Core Business Areas
- AT-001 (Govorestat): A CNS penetrant Aldose Reductase Inhibitor (ARI) being developed for Galactosemia and SORD Deficiency
Leadership and Structure
Shoshana Shendelman, Ph.D., is the Chief Executive Officer and Founder. The company has a typical biopharmaceutical structure with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- AT-001 (Govorestat): An investigational drug. It is an investigational Aldose Reductase Inhibitor (ARI) for the treatment of Galactosemia and SORD Deficiency. Currently, there are no approved therapies for these conditions, so market share data is not applicable. Competitors depend on indication. For Galactosemia no approved therapeutics currently exist, therapies are supportive measures. For SORD Deficiency, no approved therapeutics currently exist, therapies are supportive measures.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The rare disease segment is growing, driven by increased awareness and unmet medical needs.
Positioning
Applied Therapeutics focuses on rare diseases with no existing therapies. Their competitive advantage lies in their novel ARI technology and focus on specific genetic diseases.
Total Addressable Market (TAM)
The TAM for Galactosemia and SORD Deficiency is estimated to be in the hundreds of millions of dollars, dependent on pricing and penetration. The company's positioning involves securing regulatory approvals and penetrating target patient populations.
Upturn SWOT Analysis
Strengths
- Novel ARI technology
- Focus on rare diseases with unmet needs
- Experienced management team
Weaknesses
- Reliance on single drug candidate (AT-001)
- High cash burn rate
- Dependence on clinical trial success
- Commercial execution (if drug approved)
Opportunities
- Potential for regulatory approval and market exclusivity
- Expansion to other rare diseases
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing therapies for rare diseases
- Financing risk
Competitors and Market Share
Key Competitors
- ALNY
- REGN
- BIO
Competitive Landscape
Applied Therapeutics faces significant competition from established pharmaceutical companies with greater resources and experience. Their success depends on differentiating their product through efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's development stage. Any growth in the past has been based on stock price.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals for AT-001. Analyst estimates vary widely and are speculative.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Galactosemia and SORD Deficiency.
Summary
Applied Therapeutics is a high-risk, high-reward biopharmaceutical company focused on rare diseases. Its future hinges on the success of AT-001 in clinical trials and regulatory approval. The company needs to manage its cash burn and navigate the complex regulatory landscape effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Applied Therapeutics Investor Relations
- SEC Filings
- Analyst Reports (FactSet, Bloomberg)
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and analyst estimates, which are subject to change. Investing in biopharmaceutical companies involves significant risks, including clinical trial failures, regulatory hurdles, and market volatility.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Applied Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-05-14 | Interm CEO, CFO, Principal Financial Officer & Director Mr. Les D. Funtleyder | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | |
Full time employees 32 | |||
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.